A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Jun 2017
At a glance
- Drugs ASG 15ME (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Agensys
- 09 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2017.
- 09 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2017.
- 09 Jun 2017 Status changed from recruiting to active, no longer recruiting.